How effective and safe is medical cannabis as a treatment of mental disorder ? A systematic review HOCH E., NIEMANN D., von KELLER R., SCHNEIDER M., FRIEMEL C.M., PREUSS U.W., HASAN A., POGARELL O. European Archives of Psychiatry and Clinical Neuroscience, 2019 https://doi.org/10.1007/s00406-019-00984-4 Abstract We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety of cannabis-based medication in patients with mental disorders. Five data bases were systematically searched (2006—August 2018); 4 SRs (of 11 RCTs) and 14 RCTs (1629 participants) were included. Diagnoses were: dementia, cannabis and opioid dependence, psychoses/schizophrenia, general social anxiety, posttraumatic stress disorder, anorexia nervosa, [...]
Lire la suiteNovel insights into mitochondrial molecular targets of iron-inducedneurodegeneration: Reversal by cannabidiol Vanessa Kappel da Silva, Betânia Souza de Freitas, Victória Campos Dornelles,Luiza Wilges Kist, Maurício Reis Bogoc, Milena Carvalho Silvad, Emílio Luiz Streck, Jaime Eduardo Hallak, Antônio Waldo Zuardib,e, José Alexandre S. Crippab,e,Nadja Schrödera Brain Research Bulletin, 2018, 139, 1–8 https://doi.org/10.1016/j.brainresbull.2018.01.014 ABSTRACT Evidence has demonstrated iron accumulation in specific brain regions of patients suffering from neurodegen-erative disorders, and this metal has been recognized as a contributing factor for neurodegeneration. Using anexperimental model of brain iron accumulation, we have shown that iron induces severe memory deficits thatare accompanied by oxidative stress, increased apoptotic markers, and decreased [...]
Lire la suiteThe neuroprotection of cannabidiol against MPP+-induced toxicity inPC12 cells involves trkA receptors, upregulation of axonal and synapticproteins, neuritogenesis, and might be relevant to Parkinson's disease Neife Aparecida Guinaim Santos, Nádia Maria Martins, Flávia Malvestio Sisti, Laís Silva Fernandes, Rafaela Scalco Ferreira, Regina Helena Costa Queiroz, Antônio Cardozo Santos Toxicology in Vitro, 2015, 30, 231–240. http://dx.doi.org/10.1016/j.tiv.2015.11.004 a b s t r a c t Cannabidiol (CBD) is a non-psychoactive constituent of Cannabis sativa with potential to treat neurodegenerative diseases. Its neuroprotection has beenmainly associated with anti-inflammatory and antioxidant events; however, other mechanisms might be involved. We investigated the involvement of neuritogenesis, NGF receptors (trkA), NGF, and [...]
Lire la suiteCannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis : A role for A2A receptors M. Mecha, A. Feliú, P.M. Iñigo, L. Mestre, F.J. Carrillo-Salinas, C. Guaza Neurobiology of Disease, 2013, 59, 141–150 https://doi.org/10.1016/j.nbd.2013.06.016 Inflammation in the central nervous system (CNS) is a complex process that involves a multitude of mole-cules and effectors, and it requires the transmigration of blood leukocytes across the blood–brain barrier(BBB) and the activation of resident immune cells. Cannabidiol (CBD), a non-psychotropic cannabinoid constituent of Cannabis sativa, has potent anti-inflammatory and immunosuppressive properties. Yet, how this compound modifies the deleterious effects of [...]
Lire la suiteEvidences for the Anti-panic Actions of Cannabidiol Vanessa P. Soares and Alline C. Campos Current Neuropharmacology, 2017, 15, 291-299 DOI : 10.2174/1570159X14666160509123955 Abstract : Background : Panic disorder (PD) is a disabling psychiatry condition that affects approximately 5% of the worldwide population. Currently, long-term selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for PD; however, the common side-effect profiles and drug interactions may provoke patients to abandon the treatment, leading to PD symptoms relapse. Cannabidiol (CBD) is the major non-psychotomimetic constituent of the Cannabis sativa plant with antianxiety properties that has been suggested as an alternative for treating anxiety disorders. The aim of the [...]
Lire la suiteNeuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on b-amyloid-induced toxicity in PC12 cells Teresa Iuvone, Giuseppe Esposito, Ramona Esposito, Rita Santamaria, Massimo Di Rosa and Angelo A. Izzo Journal of Neurochemistry, 2004, 89, 134–141 doi:10.1111/j.1471-4159.2003 Abstract Alzheimer’s disease is widely held to be associated with oxidative stress due, in part, to the membrane action of b-amyloid peptide aggregates. Here, we studied the effect of cannabidiol, a major non-psychoactive component of the marijuana plant (Cannabis sativa) on b-amyloid peptide-induced toxicity in cultured rat pheocromocytoma PC12 cells. Following exposure of cells to b-amyloid peptide (1 lg/mL), a marked reduction in cell survival was observed. This effect [...]
Lire la suiteThe diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids : D9-tetrahydrocannabinol, cannabidiol and D9-tetrahydrocannabivarin Roger G. Pertwee British Journal of Pharmacology, 2008, 153, 199–215 doi:10.1038/sj.bjp.0707442 Cannabis sativa is the source of a unique set of compounds known collectively as plant cannabinoids or phytocannabinoids. This review focuses on the manner with which three of these compounds, (-)-trans-D9-tetrahydrocannabinol (D9-THC), (-)- cannabidiol (CBD) and (-)-trans-D9-tetrahydrocannabivarin (D9-THCV), interact with cannabinoid CB1 and CB2 receptors. D9-THC, the main psychotropic constituent of cannabis, is a CB1 and CB2 receptor partial agonist and in line with classical pharmacology, the responses it elicits appear to be strongly influenced both by [...]
Lire la suiteImproved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model Ashleigh L. Osborne, Nadia Solowij, Ilijana Babic, Xu-Feng Huang and Katrina Weston-Green Neuropsychopharmacology, 2017, 42, 1447–1457 0893-133X/17 www.neuropsychopharmacology.org doi:10.1038/npp.2017.40 Neuropsychiatric disorders such as schizophrenia are associated with cognitive impairment, including learning, memory and attention deficits. Antipsychotic drugs are limited in their efficacy to improve cognition; therefore, new therapeutic agents are required. Cannabidiol (CBD), the non-intoxicating component of cannabis, has anti-inflammatory, neuroprotective and antipsychotic-like properties; however, its ability to improve the cognitive deficits of schizophrenia remains unclear. Using a prenatal infection model, we examined the effect of chronic CBD [...]
Lire la suitePurified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis S. GIACOPPO, T. SOUNDARA RAJAN, M. GALUPPO, F. POLLASTRO, G. GRASSI, P. BRAMANTI, E. MAZZON European Review for Medical and Pharmacological Sciences, 2015, 19, 4906-4919. Abstract. – OBJECTIVE : Multiple Sclerosis (MS) is a global concern disease leading to a progressive, chronic and demyelinating condition, affecting the central nervous system (CNS). The pathology has an inflammatory/autoimmune origin; nevertheless, neuronal cell death mechanisms are not to be underestimated. The present study was designed to test the effects of intraperitoneal administration of cannabidiol (CBD), the main non-psychotropic cannabinoid of [...]
Lire la suiteCannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia : A Multicenter Randomized Controlled Trial Philip McGuire, F.R.C.Psych., F.Med.Sci., Philip Robson, M.R.C.P., F.R.C.Psych., Wieslaw Jerzy Cubala, M.D., Ph.D., Daniel Vasile, M.D., Ph.D., Paul Dugald Morrison, Ph.D., M.R.C.Psych., Rachel Barron, B.Vet.Med., M.R.C.V.S., Adam Taylor, Ph.D., Stephen Wright, F.R.C.P.(Edin), F.F.P.M. American Journal of Psychiatry, 2018, 175, 225–231. doi: 10.1176/appi.ajp.2017.17030325 Objective : Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. Method : In an exploratory double-blind parallel-group trial, patients with schizophrenia were randomized in a 1:1 ratio to receive CBD (1000 [...]
Lire la suite